Our key actions included to adjust our R&D战略 to pursue external innovation in R&D, to further optimizing our production set-up as well as our global support functions so that we become more agile 和 competitive as a company.

Delivering a winning, innovative portfolio based on a revised R&D战略

Medical dermatology remains an attractive market for innovation-focused players like LEO Pharma, 和, based on our revised strategy, LEO Pharma remains committed to developing first 和/or best-in-class treatments across broad medical dermatology indications to enable differentiation.

为此目的, we will need to develop the best available innovation, independently of whether this is accessed internally or externally. 为了实现这个目标, we are externalizing our innovation sourcing model in research 和 early development to become even more flexible in delivering therapeutics across orals, topicals 和 biologics.

This is a major shift for LEO Pharma 和 means that our early research 和 development organization will be significantly reduced 和 deliver clinical pipeline projects through strategic external partnerships. 十大网投在线官方入口的全球R&D organization will focus to deliver the adjusted pipeline 和 further outsource 和 prioritize activities, while it will also remain a key priority to maintain a strong focus on our three late-stage assets Adtralza/Adbry, delgocitinib 和 IL-22R as well as ongoing pre-clinical programs.

New GLT area brings together 全球 Product 供应, CMC Design & Development 和 全球 Procurement

We are further optiming our set-up by bringing our 全球 Product 供应, CMC Design 和 Development 和 全球 Procurement functions together to form a new area in our 全球 Leadership Team (GLT) called Technical Development & 供应. 

This will secure one clear single accountable GLT area responsible for transferring innovation from research stage into development 和 onto a commercially viable product provided to our commercial organizations. 

A new Procurement 和 External 供应 unit will be the single point of business contact towards our external partners with full delivery 和 end-to-end accountability.  

Across the corporate functions, focus will be on further reducing costs 和 sizing teams to serve a smaller organization

Although these changes will make our organization stronger in the long term, they mean that we have had to say goodbye to around 300 colleagues. We thank them for their contributions in getting us this far in our transformation towards becoming a global leader in medical dermatology.